Literature DB >> 16302816

Conformationally sampled pharmacophore for peptidic delta opioid ligands.

Denzil Bernard1, Andrew Coop, Alexander D MacKerell.   

Abstract

Opioids represent the frontline treatment for acute pain, despite their side effects, motivating efforts toward developing novel opioid analgesics. To facilitate these efforts, a novel modeling approach, the conformationally sampled pharmacophore (CSP), has been developed that increases the probability of including the receptor bound form in the model. This method, originally used for developing a nonpeptidic delta opioid efficacy pharmacophore, is extended to peptidic ligands using replica exchange molecular dynamics simulation for conformational sampling. The developed 2D CSP indicates that the spatial relationship of the basic nitrogen and the hydrophobic moiety in the delta opioid ligands differentiates activity. In addition, results indicate that both peptidic and nonpeptidic ligands have the same binding mode with the receptor. Thus, the CSP approach distinguishes both peptidic and nonpeptidic delta opioid agonists and antagonists and is anticipated to be of general utility for the development of pharmacophores for species with multiple rotatable bonds.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16302816     DOI: 10.1021/jm050785p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

1.  Molecular switch controlling the binding of anionic bile acid conjugates to human apical sodium-dependent bile acid transporter.

Authors:  Rana Rais; Chayan Acharya; Gasirat Tririya; Alexander D Mackerell; James E Polli
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

2.  Hierarchical clustering analysis of flexible GBR 12909 dialkyl piperazine and piperidine analogs.

Authors:  Kathleen M Gilbert; Carol A Venanzi
Journal:  J Comput Aided Mol Des       Date:  2006-07-20       Impact factor: 3.686

3.  Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity.

Authors:  Denzil Bernard; Andrew Coop; Alexander D MacKerell
Journal:  J Med Chem       Date:  2007-03-17       Impact factor: 7.446

Review 4.  CHARMM: the biomolecular simulation program.

Authors:  B R Brooks; C L Brooks; A D Mackerell; L Nilsson; R J Petrella; B Roux; Y Won; G Archontis; C Bartels; S Boresch; A Caflisch; L Caves; Q Cui; A R Dinner; M Feig; S Fischer; J Gao; M Hodoscek; W Im; K Kuczera; T Lazaridis; J Ma; V Ovchinnikov; E Paci; R W Pastor; C B Post; J Z Pu; M Schaefer; B Tidor; R M Venable; H L Woodcock; X Wu; W Yang; D M York; M Karplus
Journal:  J Comput Chem       Date:  2009-07-30       Impact factor: 3.376

5.  Molecular simulation of protein-surface interactions: benefits, problems, solutions, and future directions.

Authors:  Robert A Latour
Journal:  Biointerphases       Date:  2008-09       Impact factor: 2.456

6.  Inhibition of protein-protein interactions with low molecular weight compounds.

Authors:  Marilyn M Matthews; David J Weber; Paul S Shapiro; Andrew Coop; Alexander D Mackerell
Journal:  Curr Trends Med Chem       Date:  2008-01-01

7.  Consensus 3D model of μ-opioid receptor ligand efficacy based on a quantitative Conformationally Sampled Pharmacophore.

Authors:  Jihyun Shim; Andrew Coop; Alexander D MacKerell
Journal:  J Phys Chem B       Date:  2011-05-12       Impact factor: 2.991

8.  Computational ligand-based rational design: Role of conformational sampling and force fields in model development.

Authors:  Jihyun Shim; Alexander D Mackerell
Journal:  Medchemcomm       Date:  2011-05       Impact factor: 3.597

9.  Force Fields for Small Molecules.

Authors:  Fang-Yu Lin; Alexander D MacKerell
Journal:  Methods Mol Biol       Date:  2019

10.  Inhibition requirements of the human apical sodium-dependent bile acid transporter (hASBT) using aminopiperidine conjugates of glutamyl-bile acids.

Authors:  Pablo M González; Chayan Acharya; Alexander D Mackerell; James E Polli
Journal:  Pharm Res       Date:  2009-04-21       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.